Donor lymphocyte infusions (DLIs) provide effective therapy for patients with various hematological malignancies who have relapsed after allogeneic hematopoietic stem cell transplantation (HSCT). In patients with multiple myeloma (MM), DLIs can induce response rates of 40-52%. DLIs were employed as treatment for MM relapse or as prophylaxis for relapse in MM patients undergoing allo-HSCT. The clinically most relevant treatment-related morbidity with DLIs is the occurrence of graft-versus-host disease (GVHD). Secondly, graft failure and the immune escape of extramedullary plasmocytoma have been reported. The fact that previous clinical reports have documented graft-versus-myeloma (GVM) activity without GVHD suggests that at least two distinct immunocompetent cell populations mediating GVHD and/or GVM may exist. Further characterization of the effector cells such as T cells and/or NK cells and their targets may help to clarify the immune response that mediates the GVM effect. This review considers the results of clinical approaches with DLI for MM, with emphasis on strategies to prevent GVHD while preserving the GVM effect. Furthermore, currently investigated molecular antigenic targets for the GVM effect such as MM-specific idiotypic determinant of immunglobulin variable regions, several PRAME epitopes and antigenic structures encoded by cancer germline-specific genes as candidates for immunotherapy trials are discussed. Several studies have demonstrated that allogeneic hematopoietic stem cell transplantation (HSCT) can provide effective therapy for patients with MM, improve long-term survival and even cure the patient.
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Clinical experience with donor lymphocyte infusions (DLI) in multiple myeloma (MM)
Several studies have demonstrated that allogeneic hematopoietic stem cell transplantation (HSCT) can provide effective therapy for patients with MM, improve long-term survival and even cure the patient. [1] [2] [3] [4] [5] Although high-dose chemotherapy and total body irradiation prior transplantation effectively reduce the plasma-cell burden, donorderived immunocompetent cells have been shown to play an important role in the curative effects of allogeneic HSCT. [4] [5] [6] [7] [8] DLI alone have been demonstrated to induce response rates in 40-67% of patients with MM. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Experience was collected with DLI as prophylaxis [9] [10] [11] [12] for myeloma relapse or as relapse treatment [13] [14] [15] [16] [17] [18] [19] [20] after allo-HSCT.
Although a graft-versus-myeloma (GVM) effect has been documented in several case reports and small populations, [13] [14] [15] [16] [17] [18] the results must be interpreted with respect to additional chemotherapy preceding DLI administration 19 or interferon (IFN)-a 15, 19 for immunological modulation. IFN-a might enhance the GVM effect by increasing the expression of cell-surface molecules necessary for the interaction of effector cells with the neoplastic plama cell 21, 22 or by a direct antimyeloma effect. Although some patients seem to respond only to DLI when IFN-a is added, no randomized trial has been performed to evaluate the benefit from the cytokine in addition to DLIs. 23 Furthermore, corticosteroids, the most common employed treatment for graft-versus-host disease (GVHD) occurring after DLI, have antimyeloma activity and thus may contribute to a response.
The response rates in the two larger studies (25 and 27 patients) on DLI for MM relapse after allo-HSCT demonstrated response rates of 40-52% as detailed in Table 1 . 19, 20 In all, 22-28% of the responders achieved a CR and 14-30% a PR. 19, 20 Of note, in the study of Salama et al, 19 3/10 responders (30%) had received additional chemotherapy prior to DLI administration. 19 Total CD3 þ T-cell doses ranged between 1 and 330 Â 10 6 /kg body weight and responses were mostly observed after relatively high T-cell doses achieved by multiple DLIs. 19, 20 The median duration of remission were 15 months 19 and 6 months, 20 respectively. The response to DLI treatment was highly correlated with the occurrence and severity of acute GVHD in one study and 19 in the other study 20 no correlation was detectable.
GVHD is the most significant complication after DLI for MM treatment. [12] [13] [14] [15] [16] [17] [18] [19] In the two larger studies on DLI for myeloma, acute GVHD was documented in 52-56% and chronic GVHD in 26-44% of patients. 19, 20 Beside the relapse treatment of MM after HSCT, DLI have been applied as part of the transplantation strategy after nonmyeloablative regimens, [9] [10] [11] [12] as summarized in Table 2 . CD8 þ -depleted DLIs as consolidation treatment, 6-9 months after T-cell depleted allogeneic HSCT, resulting in response rate of 71%, with 43% CR. 9 Badros et al 10 conducted a trial employing nonmyeloablative HSCT and unmanipulated allogeneic PBSCT grafts from sibling in 16 poor risk, chemotherapy-refractory patients. Patients without evidence for GVHD (n ¼ 14) received DLI with dose escalation on days 21, 42 and 112. This therapeutic approach resulted in 57% CR and 29% PR at a median follow-up of 1 year. However, acute GVHD occurred in 64%, chronic GVHD occurred in 50 and 21% died of GVHD complications. Reduced-intensity transplantation, including in vivo T-cell depletion with alemtuzumab (Campath s ) and adjuvant dose-escalating DLIs in 14 patients, demonstrated a 2-year estimated overall survival and progression-free survival of 71 and 30%, respectively, 11 and at a 2.2-year follow-up of this study 12 including additional patients 58% are alive (Table 2 ). These data provide evidence that DLI can be employed as a part of the treatment strategy for patients with persistent, relapsed or progressive disease after nonmyeloablative hematopoietic cell transplantation.
Toxicity of DLIs
The clinically most relevant treatment-related morbidity with DLI is the occurrence of GVHD. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Further clinical limitations may be the immune escape of plasmocytoma in extramedullary tissues, infectious complications and graft failure. 12, 19, 24 In the study of Lokhorst et al, 20 bone marrow aplasia was observed in five of 27 patients. Four of these patients were complete donor chimeras (T and non-T cells in the peripheral blood) and one patient was a mixed chimera at the time at which DLI was given; three of five patients had grade 3 acute GVHD when bone marrow aplasia occurred. 20 Septicemia occurred in two patients who died during bone marrow aplasia. 20 Peggs et al demonstrated in a dose escalation study after reducedintensity conditioning that DLI doses of 1 Â 10 7 /kg or more are associated with a significantly increased risk of GVHD Acute GVHD is mediated primarily by donor T cells directed against multiple antigens expressed in different recipient tissues. Despite a potential overlap between GVHD and graft-versus leukemia (GVL) effect , several animal models have demonstrated the feasibility of distinguishing these two effects of donor T cells. [25] [26] [27] Different clinical strategies to preserve GVL while reducing the incidence of GVHD after DLI include infusion of limited numbers of donor T cells, sequential infusion of increasing numbers of donor T cells and infusion of selected subsets of donor T cells. [9] [10] [11] [12] [28] [29] [30] The results of clinical trials for different hematological malignancies suggest that GVL activity of DLI can be maintained in the absence of clinical GVHD. [9] [10] [11] [12] [28] [29] [30] In particular, CD8
þ T-cell depletion of the DLIs prior infusion appears to be one method for effectively reducing the incidence and severity of GVHD. 28, 29 Previous clinical trials have shown that CD4 þ T-cell-enriched infusion, obtained after depletion of CD8 þ cells, without further in vitro manipulation or activation have much less potential for GVHD induction.
28,29
Molecular targets for the GVM effect
Despite the widespread use of DLI to treat or prevent relapse, the immunological mechanisms mediating GVM activity are not yet defined. The identification of target antigens present on MM cells and absent on nonmalignant cells would be of major interest to induce MM-specific donor T cells in vitro for adoptive transfer and therefore improving the safety and efficiency of DLI therapy.
To date, MM immunotherapy trials have focused on the myeloma-specific idiotypic determinant of immunglobulin variable regions (Id) representing an individual, tumorspecific target antigen for immunotherapy. Unfortunately, the promising immunological and clinical responses to active Id vaccination obtained in patients with low-grade Bcell non-Hodgkin's lymphoma 31, 32 have so far not been found in MM patients. This could be due to the fact that, in contrast to lymphoma, the Ig is secreted in large amounts in MM, conditions that may cause the deletion of highaffinity T cells recognizing Ig-derived epitopes. 33 However, in one MM patient, the monoclonal Ig produced by the malignant plasma cells was used to immunize the donor before allogeneic bone marrow transplantation. This resulted in a detectable anti-idiotype cellular immune response in both donor and allografted recipient. 34 Other possible T-lymphocyte targets present on MM cells are encoded by genes specifically overexpressed in certain tissues (MUC1, PRAME). MUC1 is an immunogenic epithelial mucin present in an underglycosylated form on breast, pancreatic and ovarian cancer. 35 Myeloma cells were also shown to express underglycosylated MUC1 recognized by T cells in an HLA-unrestricted, but also restricted, manner. 36, 37 The PRAME gene encodes an antigen recognized by an autologous CTL clone on a melanoma cell line. 38 Furthermore, PRAME is frequently expressed in several tumor types, in some hematological malignancies such as AML carrying the t(8;21) translocation and in MM. 39, 40 Despite its low level of expression in some normal tissues (endometrium, adrenals, ovary), it is an attractive candidate for immunotherapy trials, as several PRAME epitopes are presented by different HLA molecules to specific CTL that lyse various tumor cells expressing PRAME. 38, 41 Another category of target Analysis of the MM gene expression database supplemented by immunohistochemistry for tumor protein expression in MM indicated that the cancer-testis antigen NY-ESO-1 is expressed in 460% of newly diagnosed and 100% of relapsed poor prognosis MM characterized by abnormal cytogenetics. 43 When examining the sera of MM patients, NY-ESO-1-specific antibodies were detected in 2/11 NY-ESO-1-positive and 1/21 NY-ESO-1-negative patients. 43 These and other data indicate the high immunogenicity of NY-ES0-1, both humoral and cellular, in MM. In order to further investigate the use of NY-ESO-1-specific immunotherapy in MM in the setting of autografting, a trial for patients with NY-ESO-1-positive MM, combining tandem autologous transplantation with NY-ESO-1157-C165V peptide vaccination to boost pre-existent NY-ESO-1 immunity is underway. 43 Owing to their strictly tumor-specific expression, the MAGE-type genes are promising candidates for immunotherapy trials. In MM, the cancer germline-specific genes are preferentially expressed in advanced disease state (up to 50%). 40, 44 Interestingly, a recent study comparing gene expression profiles between normal and malignant plasma cells found that the cancer germline genes were among the most upregulated genes in MM cells. 45 Since MAGEspecific CTL have been shown to lyse MM cells, it would be an attractive option to induce MAGE-specific donor T cells in vivo for adoptive transfer for MAGE-expressing MM patients with relapse after allogeneic HSCT.
The genetical alterations frequently found in MM may induce the overexpression of genes (cyclin D1, FGFR3) or hybrid transcripts 46, 47 that could be targeted as specific tumor-associated antigens.
A new way to identify MM-specific genes as targets for immunotherapeutic strategies is to compare the gene expression profiles between malignant MM cells and normal plasma cells. RNA array technology will substantially increase the number of potential targets in MM. 45, 48 By screening an MM cDNA expression library with post-DLI serum from patients responding to DLI, Bellucci et al 49 identified 13 gene products reactive with post-DLI serum. These data demonstrate the correlation of clinical response to DLI and an MM-specific antibody response and suggest that a coordinated immune response involving B cells is responsible for the GVM effect. 49 
Perspectives in DLI treatment for MM
Even with a reduction in treatment-related mortality due to reduced-intensity conditioning, success with allogeneic HSCT is hampered by the significant risk of medullary or extramedullary MM relapse.
DLI have been demonstrated to induce response rates of 42-85% as pre-emptive treatment [9] [10] [11] [12] against MM relapse after allo-HSCT and in 40-52% of MM patients as relapse treatment [13] [14] [15] [16] [17] [18] [19] [20] after nonmyeloablative allo-HSCT. The occurrence of GVHD [9] [10] [11] [12] indicates the necessity of developing novel strategies to transfer MM antigen-specific immunity induced ex vivo or in the stem cell donor to the allogeneic SCT recipient to prevent or treat relapse. Such immunity could also be a well-defined vaccine, specific for the patient's MM. Since MAGE-specific CTL have been shown to lyse MM cells, it would be an attractive option to induce MAGE-specific donor T cells in vivo for adoptive transfer for MAGE-expressing MM patients with relapse after allo-HSCT.
Donor immunization with MM idiotype protein or with other MM-specific antigens, identified by gene expression profiling, comparing malignant MM cells and normal plasma cells by high-density oligonucleotide microarray technology, 45, 48 in the setting of a nonmyeloablative HSCT, may present a novel strategy for MM treatment.
